| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
The compound targets dopamine and norepinephrine transporters (DAT and NET). It acts as a reuptake inhibitor, increasing synaptic concentrations of these monoamines, similar to other synthetic cathinones. It has minimal activity at the serotonin transporter.
|
|---|---|
| ln Vitro |
In vitro studies show that this compound inhibits dopamine reuptake with an IC50 value in the low micromolar range. It exhibits selectivity for DAT over SERT. It does not act as a releasing agent but rather as a typical reuptake inhibitor.
|
| ln Vivo |
In vivo, synthetic cathinone analogues produce stimulant effects including increased locomotor activity and hyperactivity in rodent models. They also show potential for self-administration in animal studies, indicating abuse liability similar to cocaine or methamphetamine.
|
| Enzyme Assay |
Not specified for this compound. Standard protocols for transporter binding assays use membranes from cells expressing human DAT, NET, or SERT. Competition binding with radiolabeled ligands such as [3H]WIN35,428 is measured, followed by filtration and scintillation counting.
|
| Cell Assay |
Not specified for this compound. Standard uptake inhibition assays involve HEK-293 cells expressing human transporters. Cells are incubated with the compound and a radiolabeled substrate (e.g., [3H]dopamine for DAT), and accumulated radioactivity is measured.
|
| Animal Protocol |
In vivo protocols for stimulant effects typically use open field tests in rodents. Animals receive the compound via intraperitoneal injection, and horizontal locomotor activity is recorded for 60-120 minutes. Drug discrimination and self-administration models are used to assess abuse potential.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for this specific compound are limited. Synthetic cathinones generally have high lipid solubility, rapid brain penetration, and are metabolized by hepatic cytochrome P450 enzymes, with elimination half-lives ranging from 1-4 hours in rodents.
|
| Toxicity/Toxicokinetics |
Toxicological data are primarily derived from forensic cases. Synthetic cathinones can cause sympathomimetic toxicity including hypertension, tachycardia, hyperthermia, and serotonin syndrome. Chronic use may lead to neurotoxicity and cognitive deficits.
|
| References |
[1]. α-Aminoketone derivatives. United Kingdom, GB1069797A.
|
| Additional Infomation |
This compound is a research chemical and has no approved medical use. It is classified as a controlled substance in many jurisdictions due to its abuse potential. It serves as an analytical standard for forensic toxicology and drug testing.
|
| Molecular Formula |
C14H22CLNO
|
|---|---|
| Molecular Weight |
255.78
|
| Exact Mass |
255.138
|
| CAS # |
18268-14-9
|
| PubChem CID |
119057571
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
17
|
| Complexity |
207
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LZUBTEDAWLMSJJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H21NO.ClH/c1-4-8-13(15-11(2)3)14(16)12-9-6-5-7-10-12;/h5-7,9-11,13,15H,4,8H2,1-3H3;1H
|
| Chemical Name |
1-phenyl-2-(propan-2-ylamino)pentan-1-one;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 125 mg/mL (488.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.13 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9096 mL | 19.5480 mL | 39.0961 mL | |
| 5 mM | 0.7819 mL | 3.9096 mL | 7.8192 mL | |
| 10 mM | 0.3910 mL | 1.9548 mL | 3.9096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
